Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Aldolase positively regulates of the canonical Wnt signaling pathway

Authors: Michal Caspi, Gili Perry, Nir Skalka, Shilhav Meisel, Anastasia Firsow, Maayan Amit, Rina Rosin-Arbesfeld

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

The Wnt signaling pathway is an evolutionary conserved system, having pivotal roles during animal development. When over-activated, this signaling pathway is involved in cancer initiation and progression. The canonical Wnt pathway regulates the stability of β-catenin primarily by a destruction complex containing a number of different proteins, including Glycogen synthase kinase 3β (GSK-3β) and Axin, that promote proteasomal degradation of β-catenin. As this signaling cascade is modified by various proteins, novel screens aimed at identifying new Wnt signaling regulators were conducted in our laboratory. One of the different genes that were identified as Wnt signaling activators was Aldolase C (ALDOC). Here we report that ALDOC, Aldolase A (ALDOA) and Aldolase B (ALDOB) activate Wnt signaling in a GSK-3β-dependent mechanism, by disrupting the GSK-3β-Axin interaction and targeting Axin to the dishevelled (Dvl)-induced signalosomes that positively regulate the Wnt pathway thus placing the Aldolase proteins as novel Wnt signaling regulators.
Appendix
Available only for authorised users
Literature
1.
Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006, 5: 997-1014. 10.1038/nrd2154 10.1038/nrd2154CrossRefPubMed
2.
Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P: Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science. 1996, 272: 1023-1026. 10.1126/science.272.5264.1023CrossRefPubMed
3.
Kimelman D, Xu W: beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene. 2006, 25: 7482-7491. 10.1038/sj.onc.1210055CrossRefPubMed
4.
Angers S, Moon RT: Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009, 10: 468-477.CrossRefPubMed
5.
Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M, Niehrs C: Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science. 2007, 316: 1619-1622. 10.1126/science.1137065CrossRefPubMed
6.
Skalka N, Caspi M, Caspi E, Loh YP, Rosin Arbesfeld R, Carboxypeptidase E: a negative regulator of the canonical Wnt signaling pathway. Oncogene. 2012, 32: 2836-2847.PubMedCentralCrossRefPubMed
7.
Buono P, Mancini FP, Izzo P, Salvatore F: Characterization of the transcription-initiation site and of the promoter region within the 5′ flanking region of the human aldolase C gene. Eur J Bioche / FEBS. 1990, 192: 805-811. 10.1111/j.1432-1033.1990.tb19294.x.CrossRef
8.
Arakaki TL, Pezza JA, Cronin MA, Hopkins CE, Zimmer DB, Tolan DR, Allen KN: Structure of human brain fructose 1, 6-(bis)phosphate aldolase: linking isozyme structure with function. Protein Sci Publ Protein Soc. 2004, 13: 3077-3084.CrossRef
9.
Tolan DR, Niclas J, Bruce BD, Lebo RV: Evolutionary implications of the human aldolase-A, -B, -C, and -pseudogene chromosome locations. Am J Hum Genet. 1987, 41: 907-924.PubMedCentralPubMed
10.
Arnold H, Pette D: Binding of aldolase and triosephosphate dehydrogenase to F-actin and modification of catalytic properties of aldolase. Eur J Biochem / FEBS. 1970, 15: 360-366. 10.1111/j.1432-1033.1970.tb01016.x.CrossRef
11.
Wang J, Morris AJ, Tolan DR, Pagliaro L: The molecular nature of the F-actin binding activity of aldolase revealed with site-directed mutants. J Biol Chem. 1996, 271: 6861-6865. 10.1074/jbc.271.12.6861CrossRefPubMed
12.
Buscaglia CA, Penesetti D, Tao M, Nussenzweig V: Characterization of an aldolase-binding site in the Wiskott-Aldrich syndrome protein. J Biol Chem. 2006, 281: 1324-1331. 10.1074/jbc.M506346200CrossRefPubMed
13.
Volker KW, Knull H: A glycolytic enzyme binding domain on tubulin. Arch Biochem Biophys. 1997, 338: 237-243. 10.1006/abbi.1996.9819CrossRefPubMed
14.
Rangarajan ES, Park H, Fortin E, Sygusch J, Izard T: Mechanism of aldolase control of sorting nexin 9 function in endocytosis. J Biol Chem. 2010, 285: 11983-11990. 10.1074/jbc.M109.092049PubMedCentralCrossRefPubMed
15.
Merkulova M, Hurtado-Lorenzo A, Hosokawa H, Zhuang Z, Brown D, Ausiello DA, Marshansky V: Aldolase directly interacts with ARNO and modulates cell morphology and acidic vesicle distribution. Am J Physiol Cell Physiol. 2011, 300: C1442-C1455. 10.1152/ajpcell.00076.2010PubMedCentralCrossRefPubMed
16.
Lu M, Ammar D, Ives H, Albrecht F, Gluck SL: Physical interaction between aldolase and vacuolar H + -ATPase is essential for the assembly and activity of the proton pump. J Biol Chem. 2007, 282: 24495-24503. 10.1074/jbc.M702598200CrossRefPubMed
17.
Lu M, Sautin YY, Holliday LS, Gluck SL: The glycolytic enzyme aldolase mediates assembly, expression, and activity of vacuolar H + -ATPase. J Biol Chem. 2004, 279: 8732-8739. 10.1074/jbc.M303871200CrossRefPubMed
18.
Lew CR, Tolan DR: Targeting of several glycolytic enzymes using RNA interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism. J Biol Chem. 2012, 287: 42554-42563. 10.1074/jbc.M112.405969PubMedCentralCrossRef
19.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997, 275: 1787-1790. 10.1126/science.275.5307.1787CrossRefPubMed
20.
Kusakabe T, Motoki K, Hori K: Human aldolase C: characterization of the recombinant enzyme expressed in Escherichia coli. J Biochem. 1994, 115: 1172-1177.PubMed
21.
Sakakibara M, Takahashi I, Takasaki Y, Mukai T, Hori K: Construction and expression of human aldolase A and B expression plasmids in Escherichia coli host. Biochim Biophys Acta. 1989, 1007: 334-342. 10.1016/0167-4781(89)90156-5CrossRefPubMed
22.
Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, Bicknell D, Bodmer WF, Tomlinson IPM: APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”. Proc Natl Acad Sci U S A. 2000, 97: 3352-3357. 10.1073/pnas.97.7.3352PubMedCentralCrossRefPubMed
23.
Rylatt DB, Aitken A, Bilham T, Condon GD, Embi N, Cohen P: Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. Eur J Biochem / FEBS. 1980, 107: 529-537.CrossRef
24.
Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000, 351: 95-105. 10.1042/0264-6021:3510095PubMedCentralCrossRefPubMed
25.
Cliffe A, Hamada F, Bienz M: A role of Dishevelled in relocating Axin to the plasma membrane during wingless signaling. Curr Biol CB. 2003, 13: 960-966. 10.1016/S0960-9822(03)00370-1.CrossRefPubMed
26.
Nusse R, Varmus H: Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J. 2012, 31: 2670-2684. 10.1038/emboj.2012.146PubMedCentralCrossRefPubMed
27.
Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJ, Maurice MM, Mahmoudi T, Clevers H: Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell. 2012, 149: 1245-1256. 10.1016/j.cell.2012.05.002CrossRefPubMed
28.
Warburg O, Wind F, Negelein E: The Metabolism of Tumors in the Body. J Gene Physiol. 1927, 8: 519-530. 10.1085/jgp.8.6.519.CrossRef
29.
Mhawech-Fauceglia P, Wang D, Kesterson J, Beck A, de Mesy Bentley KL, Shroff S, Syriac S, Frederick P, Liu S, Odunsi K: Aldolase mRNA expression in endometrial cancer and the role of clotrimazole in endometrial cancer cell viability and morphology. Histopathology. 2011, 59: 1015-1018. 10.1111/j.1365-2559.2011.03944.xCrossRefPubMed
30.
Ojika T, Imaizumi M, Abe T, Kato K: Immunochemical and immunohistochemical studies on three aldolase isozymes in human lung cancer. Cancer. 1991, 67: 2153-2158. 10.1002/1097-0142(19910415)67:8<2153::AID-CNCR2820670825>3.0.CO;2-ZCrossRefPubMed
31.
Peng Y, Li X, Wu M, Yang J, Liu M, Zhang W, Xiang B, Wang X, Li X, Li G, Shen S: New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer. Mol BioSyst. 2012, 8: 3077-3088. 10.1039/c2mb25286dCrossRefPubMed
32.
Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC: Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep. 2008, 19: 1045-1053.PubMed
33.
Asaka M, Kimura T, Nishikawa S, Miyazuki T, Alpert E: Decreased serum aldolase B levels in patients with malignant tumors. Cancer. 1988, 62: 2554-2557. 10.1002/1097-0142(19881215)62:12<2554::AID-CNCR2820621217>3.0.CO;2-XCrossRefPubMed
34.
Schwarz-Romond T, Merrifield C, Nichols BJ, Bienz M: The Wnt signalling effector Dishevelled forms dynamic protein assemblies rather than stable associations with cytoplasmic vesicles. J Cell Sci. 2005, 118: 5269-5277. 10.1242/jcs.02646CrossRefPubMed
35.
Levina E, Oren M, Ben-Ze’ev A: Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics. Oncogene. 2004, 23: 4444-4453. 10.1038/sj.onc.1207587CrossRefPubMed
36.
Hart MJ, De Los Santos R, Albert IN, Rubinfeld B, Polakis P: Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol CB. 1998, 8: 573-581. 10.1016/S0960-9822(98)70226-X.CrossRefPubMed
37.
Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A: Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem. 1999, 274: 10681-10684. 10.1074/jbc.274.16.10681CrossRefPubMed
Metadata
Title
Aldolase positively regulates of the canonical Wnt signaling pathway
Authors
Michal Caspi
Gili Perry
Nir Skalka
Shilhav Meisel
Anastasia Firsow
Maayan Amit
Rina Rosin-Arbesfeld
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-164

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway

Research

Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease

Research

microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer

Research

Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma

Research

Malignancy-associated metabolic profiling of human glioma cell lines using 1H NMR spectroscopy

Research

Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits